Loncastuximab Tesirine Demonstrated Substantial Single-Agent Efficacy and Manageable Safety Profile in Heavily Pretreated Chinese Patients with Relapsed or Refractory (R/R) Diffuse Large B-Cell Lymphoma (DLBCL)

被引：2

作者：

Lin, Ningjing ^{[1
]}

Sun, Xiuhua ^{[2
]}

Zhou, Hui ^{[3
]}

Zou, Liqun ^{[4
]}

Zhou, Keshu ^{[5
]}

Liu, Lihong ^{[6
]}

Yang, Haiyan ^{[7
]}

Hu, Kai ^{[8
]}

Cai, Qingqing ^{[9
]}

Liu, Yao ^{[10
]}

Jin, Jie ^{[11
]}

Zhang, Liling ^{[12
]}

Li, Wenyu ^{[13
]}

Guo, Ye ^{[14
]}

Yang, Wei ^{[15
]}

Luo, Feng ^{[16
]}

Li, Yanyan ^{[16
]}

Zhang, Mengqi ^{[16
]}

Lu, Feinan ^{[16
]}

Song, Yuqin ^{[17
]}

Zhu, Jun ^{[18
]}

机构：

[1] Beijing Canc Hosp, Dept Lymphat Oncol, Beijing, Peoples R China

[2] Dalian Med Univ, Hosp 2, Dalian, Peoples R China

[3] Cent South Univ, Hunan Canc Hosp, Affiliated Canc Hosp, Xiangya Sch Med, Changsha, Peoples R China

[4] Sichuan Univ, West China Hosp, Chengdu, Peoples R China

[5] Zhengzhou Univ, Henan Canc Hosp, Dept Hematol, Canc Hosp, Zhengzhou, Peoples R China

[6] Hebei Med Univ, Hosp 4, Shijiazhuang, Hebei, Peoples R China

[7] Zhejiang Canc Hosp, Dept Lymphat Oncol, Hangzhou, Peoples R China

[8] Beijing Boren Hosp, Dept Adult Lymphoma, Beijing, Peoples R China

[9] Sun Yat Sen Univ, Canc Cente, Guangzhou, Peoples R China

[10] Chongqing Univ, Canc Hosp, Chongqing, Peoples R China

[11] Zhejiang Univ, Dept Hematol, Affiliated Hosp 1, Sch Med, Hangzhou, Peoples R China

[12] Huazhong Univ Sci & Technol, Union Hosp, Tongji Med Coll, Ctr Canc, Wuhan, Peoples R China

[13] Guangdong Prov Peoples Hosp, Guangzhou, Peoples R China

[14] Shanghai East Hosp, Shanghai, Peoples R China

[15] China Med Univ, Dept Hematol, Shengjing Hosp, Shenyang, Peoples R China

[16] Overland Pharmaceut, Shanghai, Peoples R China

[17] Peking Univ, Key Lab Carcinogenesis & Translat Res, Dept Lymphoma, Minist Educ Beijing,Canc Hosp & Inst, Beijing, Peoples R China

[18] Peking Univ, Canc Hosp, Beijing, Peoples R China

来源：

BLOOD | 2023年 / 142卷

关键词：

D O I：

10.1182/blood-2023-173645

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

引用

页数：4

共 50 条

[21] Magrolimab in Combination with Rituximab plus Chemotherapy in Patients with Relapsed or Refractory (R/R) Diffuse Large B-Cell Lymphoma (DLBCL)
Maakaron, Joseph
Asch, Adam S.
Popplewell, Leslie L.
Collins, Graham P.
Flinn, Ian W.
Ghosh, Nilanjan
Keane, Colin
Ku, Matthew
Mehta, Amitkumar
Roschewski, Mark
O'Hear, Carol
Ren, Xuehan
Villa, Bertha
Lal, Indu
Smith, Sonali M.
Advani, Ranjana H.
BLOOD, 2022, 140 : 3728 - 3730
[22] A Phase 2b Study of Selinexor in Patients with Relapsed/Refractory (R/R) Diffuse Large B-Cell Lymphoma (DLBCL)
Kalakonda, Nagesh
Cavallo, Federica
Follows, George
Goy, Andre
Vermaat, Joost S. P.
Casasnovas, Olivier
Lavee, Orly
Maerevoet, Marie
Zijlstra, Josee
Bakhshi, Sameer
Bouabdallah, Reda
Choquet, Sylvain
Gurion, Ronit
Hill, Brian
Jaeger, Ulrich
Sancho, Juan-Manuel
Schuster, Michael
Thieblemont, Catherine
De la Cruz, Fatima
Egyed, Miklos
Mishra, Sourav
Offner, Fritz
Vassilakopoulos, Theodoros
Warzocha, Krzysztof
McCarthy, Daniel
Ma, Xiwen
Corona, Kelly
Saint-Martin, Jean-Richard
Joshi, Anita
Shah, Jatin
Van den Neste, Eric
Canales, Miguel
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2019, 19 : S248 - S249
[23] Understanding the patient experience in follicular lymphoma (FL), relapsed/refractory FL (R/R FL), and relapsed/refractory diffuse large B-cell lymphoma (R/R DLBCL)
Bell, Jill A.
Cherepanov, Dasha
Revicki, Dennis
Speck, Rebecca M.
Swett, Laura
Stumpo, Kate
Rong, Yuanxin
Gordon, Leo I.
QUALITY OF LIFE RESEARCH, 2019, 28 : S67 - S68
[24] Loncastuximab tesirine in Chinese patients with relapsed or refractory diffuse large B-cell lymphoma: a multicenter, open-label, single-arm, phase II trial
Lin, Ningjing
Sun, Xiuhua
Zhou, Hui
Zou, Liqun
Zhou, Keshu
Liu, Lihong
Yang, Haiyan
Hu, Kai
Cai, Qingqing
Liu, Yao
Jin, Jie
Zhang, Liling
Li, Wenyu
Guo, Ye
Yang, Wei
Luo, Feng
Wang, Zhenguang
Zhu, Rong
Yang, Lei
Song, Dan
Song, Yuqin
Zhu, Jun
HAEMATOLOGICA, 2025, 110 (03) : 683 - 692
[25] Patient, Caregiver, and Physician Preferences for Treatment of Relapsed or Refractory Diffuse Large B-Cell Lymphoma (R/R DLBCL)
Vukcevic, Mirko
Yung, Mallory
Khan, Mali
Houpt, Bethany
Schnell, Frederick
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2022, 22 : S376 - S377
[26] The Burden of Relapsed/Refractory (R/R) Diffuse Large B-Cell Lymphoma (DLBCL): A Systematic Literature Review (SLR)
Lenz, Georg
Rutherford, Sarah C.
Davies, Andrew
Zinzani, Pier Luigi
Salles, Gilles
Hasskarl, Jens
Margunato-Debay, Sandra
Rodrigues, Filipe
Nientker, Lisette
Balradj, Janita
Alleman, Cathelijne
BLOOD, 2018, 132
[27] Patient, caregiver, and physician preferences for treatment of relapsed or refractory diffuse large B-cell lymphoma (R/R DLBCL).
Vukcevic, Mirko
Yung, Mallory
Khan, Maliha
Schnell, Frederick Mark
JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16) : E18710 - E18710
[28] Inpatient treatment of relapsed/refractory diffuse large B-cell lymphoma (r/r DLBCL): A health economic perspective
Moertl, Bernhard
Dreyling, Martin
Schmidtl, Christian
Hoster, Eva
Schoel, Wolfgang
V. Bergwelt-Baildon, Michael
Berger, Karin
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2022, 22 (07): : 474 - 482
[29] Interim evaluation of a targeted radiotherapeutic, CLR 131, in relapsed/refractory diffuse large B-cell lymphoma patients (R/R DLBCL)
Longcor, J.
Oliver, K.
Friend, J.
Callandar, N.
ANNALS OF ONCOLOGY, 2019, 30 : 435 - 435
[30] Health-Related Quality of Life, Symptoms, and Tolerability of Loncastuximab Tesirine in Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma
Spira, Alexander
Zhou, Xiaolei
Chen, Lei
Gnanasakthy, Ari
Wang, Luqiang
Ungar, David
Curiel, Rafael
Liao, Laura
Radford, John
Kahl, Brad
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2022, 22 (03): : 158 - 168

← 1 2 3 4 5 →